Active — Not RecruitingPhase 3

Safety and Efficacy of Intralesional 0.5% Triamcinolone Acetonide in 0.2% Fluconazole Solution vs 0.1% Topical Mometasone Furoate With 2% Miconazole Nitrate Cream in the Treatment of Chronic Paronychia: An Intraindividual Randomized Controlled Trial.

Egypt21 participantsStarted 2024-08-17

Plain-language summary

Our objective is to compare the efficacy and safety of intralesional corticosteroids + fluconazole solution to corticosteroid with an antifungal topical preparation, in the management of chronic paronychia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with chronic paronychia affecting ≥ 2 fingernails in the dominant hand.
✓. Patients not receiving any relevant systemic treatment for at least 4 weeks before initiation of our study
✓. Patients not receiving any relevant topical treatment for at least 2 weeks before initiation of our study

Exclusion criteria

✕. Patient with peripheral vascular disease or Raynaud's phenomenon
✕. Pregnant and lactating females
✕. Patients with autoimmune diseases e.g., connective tissue diseases, psoriasis, reactive arthritis, and pemphigus.
✕. Patients with solid or hematological malignancies.
✕. Patients on systemic drugs that are known to cause chronic paronychia e.g. retinoids.
✕. Patients with any visible focus of infection at the injection site or in the vicinity, including patients with superimposed attack of acute paronychia.
✕. Onychomycosis or any associated nail disease

What they're measuring

Comparison between the chronic paronychia severity index scale before and after treatment in each group

Timeframe: 4 months

Comparison of the change in chronic paronychia severity index scale between both groups

Timeframe: 4 months

Comparison of percentage of patients who achieved complete response (chronic paronychia severity index scale =0) between both groups.

Timeframe: 4 months

Trial details

NCT IDNCT07311759

SponsorCairo University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-04

View on ClinicalTrials.gov More Chronic Paronychia trials

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients with chronic paronychia affecting ≥ 2 fingernails in the dominant hand.
✓. Patients not receiving any relevant systemic treatment for at least 4 weeks before initiation of our study
✓. Patients not receiving any relevant topical treatment for at least 2 weeks before initiation of our study

Exclusion criteria

✕. Patient with peripheral vascular disease or Raynaud's phenomenon
✕. Pregnant and lactating females
✕. Patients with autoimmune diseases e.g., connective tissue diseases, psoriasis, reactive arthritis, and pemphigus.
✕. Patients with solid or hematological malignancies.
✕. Patients on systemic drugs that are known to cause chronic paronychia e.g. retinoids.
✕. Patients with any visible focus of infection at the injection site or in the vicinity, including patients with superimposed attack of acute paronychia.
✕. Onychomycosis or any associated nail disease

What they're measuring

Comparison between the chronic paronychia severity index scale before and after treatment in each group

Timeframe: 4 months

Comparison of the change in chronic paronychia severity index scale between both groups

Timeframe: 4 months

Comparison of percentage of patients who achieved complete response (chronic paronychia severity index scale =0) between both groups.

Timeframe: 4 months